camidanlumab tesirine
mAbexperimentalADC
Camidanlumab tesirine is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin. The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04052997)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-2 receptor alpha chainBINDING AGENT
Interleukin-2 receptor alpha chain binding agent
- DNACROSS-LINKING AGENT
DNA cross-linking agent
- Peripheral myelin protein 22INHIBITOR
PMP22 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- pyrrolobenzodiazepine
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCamidanlumab tesirine ↗
- ChEMBLCHEMBL4297871 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04052997 | Phase 2 | Sep 30, 2019 | ADC Therapeutics SARL |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ADC Therapeutics SARL | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1